Click here to see
the Case Study
Step 01
tHE idea
The Objective
The scientific journal editor proposes illustration services to authors who wish to publish in their peer-reviwed journal.
As scientific graphic designer, I then intervene to adapt the author's graphical abstract or figure to journal guidelines and style.
Step 02
tHE brief
Peer-reviewed journal - IF: 9.1
Journal style
Editor's guidelines include a precise format for the graphical abstract: 1920 px x 1080 px.
Myriad Pro font is preferred and should not be smaller than 7 pt
Colors should be adapted for color-blind people: elements that need to be identified or differentiated need to be seen by at least the most common types of color blindness (Protanopia and Deuteranopia).
A color palette has been defined in agreement with the editor.
Step 03
tHE abstract
In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell–Related Injury
Drug repurposing is a valuable strategy for rare diseases. Sickle cell disease (SCD) is a rare hereditary hemolytic anemia accompanied by acute and chronic painful episodes, most often in the context of vaso-occlusive crisis (VOC). Although progress in the knowledge of pathophysiology of SCD have allowed the development of new therapeutic options, a large fraction of patients still exhibits unmet therapeutic needs, with persistence of VOCs and chronic disease progression. Here, we show that imatinib, an oral tyrosine kinase inhibitor developed for the treatment of chronic myelogenous leukemia, acts as multimodal therapy targeting signal transduction pathways involved in the pathogenesis of both anemia and inflammatory vasculopathy of humanized murine model for SCD. In addition, imatinib inhibits the platelet-derived growth factor-B–dependent pathway, interfering with the profibrotic response to hypoxia/reperfusion injury, used to mimic acute VOCs. Our data indicate that imatinib might be considered as possible new therapeutic tool for chronic treatment of SCD.
Thank you